CLINICAL TRIALS PROFILE FOR ZONTIVITY
✉ Email this page to a colleague
All Clinical Trials for ZONTIVITY
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02394730 ↗ | Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints | Completed | Merck Sharp & Dohme Corp. | Phase 1/Phase 2 | 2015-09-01 | ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks. |
| NCT02394730 ↗ | Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1/Phase 2 | 2015-09-01 | ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks. |
| NCT02394730 ↗ | Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints | Completed | University of Melbourne | Phase 1/Phase 2 | 2015-09-01 | ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks. |
| NCT02394730 ↗ | Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints | Completed | University of Minnesota | Phase 1/Phase 2 | 2015-09-01 | ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks. |
| NCT02394730 ↗ | Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 1/Phase 2 | 2015-09-01 | ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks. |
| NCT02394730 ↗ | Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints | Completed | Kirby Institute | Phase 1/Phase 2 | 2015-09-01 | ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZONTIVITY
Condition Name
Clinical Trial Locations for ZONTIVITY
Trials by Country
Clinical Trial Progress for ZONTIVITY
Clinical Trial Phase
Clinical Trial Sponsors for ZONTIVITY
Sponsor Name
